The high clinical need led to two recently approved ADCs, i.e. the CD30-targeting Brentuximab vedotin (Adcetris) to treat relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma and HER2-targeting Trastuzumab emtansine (Kadcyla) to treat relapsed or chemotherapy refractory HER2+ breast cancer [5, 6]. Here, ERBB2 is linked to Hodgkins lymphoma.